Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dutasteride

FDA-approved product (capsule, oral), marketed as Avodart, Dutasteride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Dutasteride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Benign prostatic hyperplasia
  • Prostate adenocarcinoma
  • Prostate carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Testosterone-5-alpha reductase inhibitors
FDA pharmacologic class
5-alpha Reductase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Dutasteride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-10.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dutasteride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Bioequivalence Study of Dutasteride Five 0.1 mg and One 0.5 mg Soft Gelatin Capsules in Healthy Male Volunteers

    NCT01929330 · start 2013-09-23

    Registered record
    Registry ID
    NCT01929330
    Conditions
    Alopecia
    Interventions
    GI198745 0.1 mg; GI198745 0.5 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-09-23
    Completion
    2014-01-09
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlopecia
    InterventionGI198745 0.1 mg; GI198745 0.5 mg
    PhasePhase 1
    Registry statusCompleted

  • Safety and Pharmacokinetic Interaction Study of Tadalafil and Dutasteride

    NCT01942551 · start 2013-09

    Registered record
    Registry ID
    NCT01942551
    Conditions
    Benign Prostate Hyperplasia
    Interventions
    Tadalafil; Dutasteride
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-09
    Completion
    2013-12
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostate Hyperplasia
    InterventionTadalafil; Dutasteride
    PhasePhase 1
    Registry statusCompleted

  • The Changes of Urine Growth Factors Level

    NCT06282731 · start 2013-05-31

    Registered record
    Registry ID
    NCT06282731
    Conditions
    Benign Prostatic Hyperplasia
    Interventions
    Silodosin
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2013-05-31
    Completion
    2017-04-27
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia
    InterventionSilodosin
    PhaseEarly phase 1
    Registry statusCompleted

  • JALYN for Benign Prostatic Hyperplasia (BPH) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

    NCT01830829 · start 2013-04

    Registered record
    Registry ID
    NCT01830829
    Conditions
    Benign Prostatic Hyperplasia; Chronic Prostatitis
    Interventions
    Jalyn; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2013-04
    Completion
    2014-10
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia; Chronic Prostatitis
    InterventionJalyn; Placebo
    PhasePhase 3
    Registry statusTerminated

  • Bioequivalence - Duodart Against Avodart & Omnic

    NCT01657851 · start 2012-08-23

    Registered record
    Registry ID
    NCT01657851
    Conditions
    Prostatic Hyperplasia
    Interventions
    dutasteride/tamsulosin; dutasteride; tamsulosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-08-23
    Completion
    2012-12-05
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    Interventiondutasteride/tamsulosin; dutasteride; tamsulosin
    PhasePhase 1
    Registry statusCompleted

  • Finasteride, Dutasteride and Insulin Action

    NCT01923090 · start 2012-08

    Registered record
    Registry ID
    NCT01923090
    Conditions
    Healthy Volunteers
    Interventions
    Finasteride; Dutasteride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2012-08
    Completion
    2013-10
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionFinasteride; Dutasteride
    PhasePhase 2
    Registry statusUnknown

  • Safety and Efficacy of 0.5mg Dutasteride and 0.4mg Tamsulosin Combination Once Daily for Six Months for Benign Prostatic Hyperplasia

    NCT01673490 · start 2012-06-29

    Registered record
    Registry ID
    NCT01673490
    Conditions
    Prostatic Hyperplasia
    Interventions
    Dutasteride/Tamsulosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2012-06-29
    Completion
    2015-03-20
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    InterventionDutasteride/Tamsulosin
    PhasePhase 4
    Registry statusTerminated

  • Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer

    NCT01547299 · start 2012-03-31

    Registered record
    Registry ID
    NCT01547299
    Conditions
    Prostate Cancer
    Interventions
    Enzalutamide; Leuprolide; Dutasteride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-03-31
    Completion
    2013-11-30
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionEnzalutamide; Leuprolide; Dutasteride
    PhasePhase 2
    Registry statusCompleted

  • STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling

    NCT01368003 · start 2011-04

    Registered record
    Registry ID
    NCT01368003
    Conditions
    Adenocarcinoma of the Prostate
    Interventions
    STA9090; STA9090 with Dutasteride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2011-04
    Completion
    2012-11
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenocarcinoma of the Prostate
    InterventionSTA9090; STA9090 with Dutasteride
    PhasePhase 2
    Registry statusWithdrawn

  • Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer

    NCT01342367 · start 2010-12-17

    Registered record
    Registry ID
    NCT01342367
    Conditions
    Prostate Cancer
    Interventions
    Bicalutamide; Dutasteride; Finasteride; Radiation
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Active not recruiting
    Start
    2010-12-17
    Completion
    2026-02
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionBicalutamide; Dutasteride; Finasteride; Radiation
    PhaseNot applicable
    Registry statusActive not recruiting

  • Benefits of Adherence to 5-alpha Reductase Inhibitor Treatment in Men With Enlarged Prostate: An Assessment of Medicare and Medicaid Patients Using the MarketScan Database

    NCT01376258 · start 2010-10

    Registered record
    Registry ID
    NCT01376258
    Conditions
    Prostatic Hyperplasia
    Interventions
    5ARI
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-10
    Completion
    2010-12
    Enrolment
    28,903

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    Intervention5ARI
    PhaseNot recorded
    Registry statusCompleted

  • A Study to Determine the Bioavailability of a Fixed Dose Combination Product of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) Relative to Co-administration of the Individual Components in Healthy Male Subjects of North East Asian and Non-Asian Ancestry.

    NCT01254071 · start 2010-09-10

    Registered record
    Registry ID
    NCT01254071
    Conditions
    Prostatic Hyperplasia
    Interventions
    Dutasteride (0.5mg); Tamsulosin hydrochloride (0.2mg); fixed dose combination product of duatsteride (0.5mg) and tamsulosin hydrochloride (0.2mg)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-09-10
    Completion
    2010-12-21
    Enrolment
    86

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    InterventionDutasteride (0.5mg); Tamsulosin hydrochloride (0.2mg); fixed dose combination product of duatsteride (0.5mg) and tamsulosin hydrochloride (0.2mg)
    PhasePhase 1
    Registry statusCompleted

  • Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia

    NCT01332487 · start 2010-08

    Registered record
    Registry ID
    NCT01332487
    Conditions
    Prostatic Hyperplasia
    Interventions
    5ARI + AB
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-08
    Completion
    2010-08
    Enrolment
    4,068

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    Intervention5ARI + AB
    PhaseNot recorded
    Registry statusCompleted

  • Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy

    NCT01435954 · start 2010-08

    Registered record
    Registry ID
    NCT01435954
    Conditions
    Benign Prostatic Hyperplasia
    Interventions
    Early combination therapy; Delayed combination therapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-08
    Completion
    2011-03
    Enrolment
    13,551

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia
    InterventionEarly combination therapy; Delayed combination therapy
    PhaseNot recorded
    Registry statusCompleted

  • Establishing the Benefits of Adherence to Enlarged Prostate Treatment: A Validation Study Linking Adherence to Outcomes Using the Market Scan Database

    NCT01381510 · start 2010-06

    Registered record
    Registry ID
    NCT01381510
    Conditions
    Prostatic Hyperplasia
    Interventions
    5-alpha Reductase Inhibitor (5ARI)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-06
    Completion
    2010-08
    Enrolment
    54,459

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    Intervention5-alpha Reductase Inhibitor (5ARI)
    PhaseNot recorded
    Registry statusCompleted